Publications

For an updated list, please follow the Google Scholar link 

  1. Sevim Kahraman, Debasish Manna#, Ercument Dirice#, Basudeb Maji, Jonnell Small, Bridget Wagner, Amit Choudhary, and Rohit Kulkarni. Harnessing Reaction-Based Probes to Preferentially Target Pancreatic b-Cells and b-Like Cells. Life Science Alliance. 2021, In press.

  2. M Lee#, B Maji#, D Manna#, J Small, B Wagner, A Choudhary. Native Zinc Catalyzes Selective and Traceless Release of Small Molecules in β-Cells. Journal of the American Chemical Society, 2020,142, 6477-6482. # Equal contribution. (IF 14.6)

  3. B Maji, SA Gangopadhyay, M Lee, M Shi, P Wu, R Heler, B Mok, D Lee, B Paul, V Dančík, MF Mesleh, A Vetere, LA Marraffini, DR Liu, PA Clemons, BK Wagner and A Choudhary. A high- throughput platform to identify small-molecule inhibitors of CRISPR-Cas9. Cell, 2019, 167, 1067- 1079. Highlighted in more than 12 science media reports. (IF 38.6)

  4. B Maji,a CL Moore,a B Zetsche, SE Volz, F Zhang, MD Shoulders and A Choudhary.   Multi-Dimensional Chemogenic Control of CRISPR-Cas9. Nature Chemical Biology, 2017, 13, 9-11. aEqual contribution. (Highlighted by Nat. Chem. Biol. News & Views. doi: 10.1038/nchembio.2243.) (IF 12.6) 

  5. D Manna, B Maji, S. Gangopadhyay, and A Choudhary. A singular system with precise dosing and spatiotemporal control of CRISPR-Cas9. Angew. Chem. Int., 2019, 58, 6285-6289. (IF 13.0)

  6. SA Gangopadhyay, K Cox, D Manna, D Lim, B Maji, Q Zhou and A Choudhary. Precision control of CRISPR-Cas9 using small molecules and light. Biochemistry, 2019, 58, 234–244. (IF 3.0)

  7. MH Kaulage,a B Maji,a S Pasadi, A Ali, S Bhattacharya and K Muniyappa. Targeting G-quadruplex  DNA structures in the telomere and oncogene promoter  regions  by  benzimidazole‒carbazole ligands. European Journal of Medicinal Chemistry, 2018, 148, 178-194. aEqual contribution. (IF 5.6)

  8. N Dey, B Maji and S Bhattacharya. Motion Induced Change in Emission as an Effective Strategy for Ratiometric Probing of Human Serum Albumin and Trypsin in a Wide Range of Biological Fluids. Chemistry – An Asian Journal, 2018, 13, 664-671. (IF 3.8)

  9. N Dey, B Maji and S Bhattacharya. A Unique Example of Excitation Triggered Alteration in Sensing Behavior of Fluorescent Organic Nanoaggregates: A Multifaceted Detection Probe for Caffeine in Real- Life Samples. Analytical Chemistry, 2018, 90, 821–829. (IF 6.8)

  10. MH Kaulage, B Maji, S Pasadi, S Bhattacharya and K Muniyappa. Novel ruthenium azo-quinoline complexes with enhanced photonuclease activity in human cancer cells. European Journal of Medicinal Chemistry, 2017, 139, 1016-1029. (IF 5.6)

  11. T Hussain, D Saha, G Purohit, A Kar, A Mukherjee, S Sharma, S Sengupta, P Dhapola, B Maji et al. Transcriptional control of CDKN1A (p21/CIP1/WAF1) by TRF2 through the REST repressor complex. Scientific Reports, 2017, 7, 11541. (IF 4.0)

  12. M Kaulage, B Maji, J Bhat, Y Iwasaki, S Chatterjee, S Bhattacharya, K Muniyappa. Discovery and Structural Characterization of G-quadruplex DNA in Human Acetyl-CoA Carboxylase Gene Promoters: Its Role in Transcriptional Regulation and as a Therapeutic Target for Human Disease. Journal of Medicinal Chemistry, 2016, 59, 5035-5050. (IF 6.2)

  13. B Maji, K Kumar, K Muniyappa, and S. Bhattacharya, New dimeric carbazole–benzimidazole mixed ligands for the stabilization of human telomeric G-quadruplex DNA and as telomerase inhibitors. A remarkable influence of the spacer. Organic & Biomolecular Chemistry, 2015,13, 8335-8348. (IF 3.6)

  14. B Maji, K Kumar, M Kaulage, K Muniyappa and S Bhattacharya, Design and Synthesis of New Benzimidazole–Carbazole Conjugates for the Stabilization of Human Telomeric DNA, Telomerase Inhibition, and Their Selective Action on Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 6973-6988. (IF 6.2)

  15. B Maji and S Bhattacharya, Advances in the molecular design of potential anticancer agents via targeting of human telomeric DNA. Chemical Communications. 2014, 50, 6422-6438. (IF 6.0)

  16. B Maji, SK Samanta and S Bhattacharya, Role of DNA Secondary Structures in the Reversible Dispersion/Precipitation and Separation of Metallic and Semiconducting Single-walled Carbon Nanotubes. Nanoscale, 2014, 6, 3721-3730. (IF 6.9)

  17. B Maji and S Bhattacharya, Molecular design of synthetic benzimidazoles for the switchover of the duplex to G-quadruplex DNA recognition. Chimia 2013, 67, 39-43. (IF 1.2)

  18. A Paul, B Maji, SK Misra, AK Jain, K Muniyappa and S Bhattacharya, Stabilization and structural alteration of the G-quadruplex DNA made from the human telomeric repeat mediated by Tröger's base based novel benzimidazole derivatives. Journal of Medicinal Chemistry, 2012, 55, 7460-7471. (IF 6.2)

  19. A Paul, AK Jain, SK Misra, B Maji, K Muniyappa and S Bhattacharya, Binding of gemini bisbenzimidazole drugs with human telomeric G-quadruplex dimers: Effect of the spacer in the design of potent telomerase inhibitors. PLoS ONE, 2012, 7, e39467. (IF 2.7)

  20. AK Jain, A Paul, B Maji, SK Misra, K Muniyappa and S Bhattacharya, Dimeric 1,3-Phenylene- bis(piperazinyl benzimidazole)s: Synthesis and structure-activity investigations on their binding with human telomeric G-quadruplex DNA and telomerase inhibition properties. Journal of Medicinal Chemistry, 2012, 55, 2981-2993. (IF 6.2)

  21. AD Tiwari, AK Mishra, SB Mishra, BB Mamba, B Maji and S Bhattacharya, Synthesis and DNA binding studies of Ni(II), Co(II), Cu(II) and Zn(II) metal complexes of N 1,N 5-bis[pyridine-2-methylene]- thiocarbohydrazone Schiff-base ligand. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2011, 79, 1050-1056. (IF 2.9)

 

 

Patents

  1. CRISPR-CAS systems having destabilization domains, US Patent WO/2018/005,873, 2018.

  2. Inhibitors of RNA guided nucleases and uses thereof. Pub. No.: WO/2018/085288. Publication Date:11.05.2018.

  3. Inhibitors of RNA-guided nuclease target binding and uses thereof. WO/2020/068304.

  4. Targeted delivery to beta cells. US patent WO2018195486A1 WIPO (PCT), 2018.

  5. Methods and compositions for optochemical control of crispr-cas9. WO / 2020/041380, 2018.

  6. Crispr protein inhibitors, U.S. Provisional Patent Application No. 62/579,727.

Key Publications

We are proud to showcase the results of research undertaken by members of our interdisciplinary Research Lab. Our work and findings have been published in a number of prestigious publications in our field.

NCB_edited_edited.jpg

Nature Chemical Biology

cover_edited.jpg

Cell

2017

Cas9-based technologies have transformed genome engineering and the interrogation of genomic functions, but methods to control such technologies across numerous dimensions—including dose, time, specificity, and mutually exclusive modulation of multiple genes—are still lacking. We conferred such multidimensional controls to diverse Cas9 systems by leveraging small-molecule-regulated protein degron domains. Application of our strategy to both Cas9-mediated genome editing and transcriptional activities opens new avenues for systematic genome interrogation.

Read More

2 May 2019

Highlights


Developed high-throughput assays for SpCas9 and performed a small-molecule screen

Identified reversible and cell-permeable inhibitors that disrupt SpCas9-DNA binding

Inhibitors allow dose and temporal control of (non)-nuclease-based SpCas9 systems

Identified a pharmacophore for SpCas9 inhibition using structure-activity studies

Read More

March 16, 2020

The loss of insulin-producing β-cells is the central pathological event in type 1 and 2 diabetes, which has led to efforts to identify molecules to promote β-cell proliferation, protection, and imaging. However, the lack of β-cell specificity of these molecules jeopardizes their therapeutic potential. A general platform for selective release of small-molecule cargoes in β-cells over other islet cells ex vivo or other cell-types in an organismal context will be immensely valuable in advancing diabetes research and therapeutic development. Here, we leverage the unusually high Zn(II) concentration in β-cells to develop a Zn(II)-based prodrug system to selectively and tracelessly deliver bioactive small molecules and fluorophores to β-cells. The Zn(II)-targeting mechanism enriches the inactive cargo in β-cells as compared to other pancreatic cells; importantly, Zn(II)-mediated hydrolysis triggers cargo activation. This prodrug system, with modular components that allow for fine-tuning selectivity, should enable the safer and more effective targeting of β-cells.